Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists
作者:David L. Gray、Wenjian Xu、Brian M. Campbell、Amy B. Dounay、Nancy Barta、Susan Boroski、Lynne Denny、Lori Evans、Nancy Stratman、Al Probert
DOI:10.1016/j.bmcl.2009.10.014
日期:2009.12
including attention deficit hyperactivity disorder (ADHD) and depression. Targeted screening of NRI-active compounds for binding to the 5-HT1A receptor provided a series of thiomorpholinone hits with this dual activity profile. Several iterations of design, synthesis, and testing led to substituted piperidine diphenyl ethers which are potent NRIs with 5-HT1A partial agonist properties. In addition,
这都是去甲肾上腺素再摄取抑制剂(NRI)和5-HT的化合物阿部分激动剂可具有治疗神经精神障碍包括注意力缺陷多动障碍(ADHD)和抑郁症的潜力。针对与5-HT 1A受体结合的NRI活性化合物的靶向筛选,提供了一系列具有这种双重活性特征的硫吗啉代酮。设计,合成和测试导致取代的哌啶二苯醚作为强力的NRI与5-HT1的若干次迭代一个部分激动剂性质。此外,这些分子的优化提供了对多巴胺(DAT)和5-羟色胺(SERT)再摄取转运蛋白具有NRI选择性的化合物。单胺和5-HT 1A 还介绍了从已开发的哌啶二苯醚系列中选择的化合物的体外功能活性。